检索结果 - Kevin X. Chen
- Showing 1 - 4 results of 4
-
1
-
2
-
3
HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib 由 Douglas D. Fang, Bin Zhang, Qingyang Gu, Maruja E. Lira, Qiang Xu, Hongye Sun, Maoxiang Qian, Weiqi Sheng, Mark Ozeck, Zhenxiong Wang, Cathy Zhang, Xinsheng Chen, Kevin X. Chen, Jian Li, Shu‐Hui Chen, James G. Christensen, Mao Mao, Chi-Chung Chan
出版 2014Artigo -
4
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor 由 Ashok Arasappan, Frank Bennett, Stéphane Bogen, Srikanth Venkatraman, Melissa L. Blackman, Kevin X. Chen, Siska Hendrata, Yuhua Huang, Regina Huelgas, Latha G. Nair, Angela I. Padilla, Weidong Pan, R. E. PIKE, Patrick Pinto, Sumei Ruan, Mousumi Sannigrahi, Francisco Velázquez, Bancha Vibulbhan, Wanli Wu, Weiying Yang, Anil K. Saksena, Viyyoor Girijavallabhan, Neng‐Yang Shih, Jianshe Kong, Tao Meng, Yan Jin, J.K.Y. Wong, Paul E. McNamara, Andrew Prongay, Vincent Madison, John J. Piwinski, Kuo-Chi Cheng, Richard A. Morrison, Bruce A. Malcolm, Xiao Tong, Robert Ralston, F. George Njoroge
出版 2010Artigo
相关主题
Medicine
Biology
Gene
Genetics
Molecular biology
ALK inhibitor
Acetylation
Anaplastic lymphoma kinase
Anatomy
Antiretroviral therapy
Astrogliosis
Axon
Biochemistry
Boceprevir
Cancer research
Cell biology
Cellular differentiation
Central nervous system
Chemistry
Chromatin
Crizotinib
Diffuse axonal injury
Enhancer
Enhancer RNAs
Enzyme
Epigenetics
Fusion gene
Fusion protein
Hepatitis C virus
Histone